Table 6.

Prevalence and attribution of HPV types in vaginal cancers

YearFirst authornMultitype infections (%)Percentage of specimens testing positive for individual HPV types
Any HPV type*
6111618313335394551525658596668707382
Vaginal squamous cell cancers (10)
2002Daling503.00.00.060.012.10.00.00.00.00.00.00.00.00.00.00.00.00.00.00.072.7
Pooled prevalence503.00.00.060.012.10.00.00.00.00.00.00.00.00.00.00.00.00.00.00.072.7
95% CI, lower0.00.046.24.80.00.00.00.00.00.00.00.00.00.00.00.00.00.00.0
95% CI, upper10.410.472.427.310.410.47.110.410.410.410.410.410.410.410.410.410.410.410.4
Multitype adjusted330.00.063.29.50.00.00.00.00.00.00.00.00.00.00.00.00.00.00.0
95% CI, lower0.00.046.23.30.00.00.00.00.00.00.00.00.00.00.00.00.00.00.0
95% CI, upper10.410.477.524.110.410.410.410.410.410.410.410.410.410.410.410.410.410.410.4
  • * As determined by consensus PCR primers sensitive to positivity for at least 15 HPV types.

  • Data for additional cases and HPV typing provided by the authors. In the study, HPV testing methods changed over time. Early testing of specimens (n = 17) was conducted for individual HPV types 16 and 35 (HPV testing for types 6/11, 18/45, and 31/33 were combined in single cocktails). Later testing was conducted for a much broader spectrum of individual HPV types (n = 33). In the table, prevalence data are reported across all specimens for HPV types 16 and 35, whereas only specimens tested during the latter period are included in results for the remaining HPV types as earlier testing for these types individually was not conducted. Only specimens tested during the latter period are included in the multitype adjusted HPV data, as the earlier testing covered <8 individually evaluable HPV types.

  • n refers to total number of lesions with any HPV typing data. By individual HPV type, number of observations varies depending on the number of types for which data were available within each study.